Viekira Pak

How AbbVie Could Hammer Gilead's Hepatitis C Franchise
How AbbVie Could Hammer Gilead's Hepatitis C Franchise
Investors Business Daily
AbbVie
Gilead Sciences
hepatitis C
Vosevi
Harvoni
Sovaldi
Epclusa
Viekira Pak
Flag link:
3 Biggest Risks for AbbVie in 2017
3 Biggest Risks for AbbVie in 2017
Motley Fool
AbbVie
Humira
biosimilars
Imbruvica
Viekira Pak
Elagolix
risankizumab
Flag link:
3 Things AbbVie's Management Said While Its Stock Got Hammered
3 Things AbbVie's Management Said While Its Stock Got Hammered
Motley Fool
AbbVie
earnings
Humira
Imbruvica
Viekira Pak
Flag link:
AbbVie's Viekira Pak Sales Plummet in Q3
AbbVie's Viekira Pak Sales Plummet in Q3
Motley Fool
AbbVie
Viekira Pak
eanrings
Flag link:
AbbVie Inc: New Drugs May Overcome Humira Loss
AbbVie Inc: New Drugs May Overcome Humira Loss
Bidness, ETC
AbbVie
Humira
Rova-T
Venclexta
Imbruvica
Viekira Pak
Flag link:
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAKwithout Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAKwithout Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
Yahoo
AbbVie
FDA
Viekira Pak
hepatitis C
Flag link:
Will Merck Encroach On Gilead's Harvoni Territory?
Will Merck Encroach On Gilead's Harvoni Territory?
Yahoo/Benzinga
Merck
Gilead
Harvoni
AbbVie
hepatitis C
Viekira Pak
Zepatier
Flag link:
Harvoni’s New Label Gives Gilead Edge Over AbbVie
Harvoni’s New Label Gives Gilead Edge Over AbbVie
Bidness, ETC
Harvoni
labeling
Gilead Sciences
AbbVie
Viekira Pak
hepatitis C
Flag link:
3 Slides That Perfectly Sum Up Where AbbVie Is Headed Next
3 Slides That Perfectly Sum Up Where AbbVie Is Headed Next
Motley Fool
AbbVie
Humira
Imbruvica
Viekira Pak
Flag link:
AbbVie Is Expected to Strengthen Its Position in Virology in 4Q15
AbbVie Is Expected to Strengthen Its Position in Virology in 4Q15
Yahoo/Market Realist
AbbVie
hepatitis C
Lupron
Duodopa
Creon
Viekira Pak
Flag link:
AbbVie's Management Just Made Some Pretty Bold Predictions
AbbVie's Management Just Made Some Pretty Bold Predictions
Motley Fool
AbbVie
Humira
Viekira Pak
Flag link:
Gilead Faces Troubled HCV Scripts as AbbVie Scripts Go Up
Gilead Faces Troubled HCV Scripts as AbbVie Scripts Go Up
Bidness, ETC
Gilead Sciences
AbbVie
hepatitis C
Sovaldi
Harvoni
Viekira Pak
Flag link:
Is Merck & Co. About to Derail Gilead Sciences?
Is Merck & Co. About to Derail Gilead Sciences?
Motley Fool
Merck
Gilead Sciences
grazoprevir/elbasvir
Viekira Pak
AbbVie
Flag link:
AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK to Treat Genotype 1 Chronic Hepatitis C Virus Infection
AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK to Treat Genotype 1 Chronic Hepatitis C Virus Infection
Yahoo
AbbVie
hepatitis C
Viekira Pak
Flag link:
AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis
AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis
Yahoo
AbbVie
Viekira Pak
hepatitis C
Flag link:
Express Scripts to maintain availability of AbbVie's hep C drug
Express Scripts to maintain availability of AbbVie's hep C drug
Yahoo/Reuters
Express Scripts
AbbVie
hepatitis C
Viekira Pak
Flag link:
FDA's Warning Shakes Up Hep C Landscape
FDA's Warning Shakes Up Hep C Landscape
Investopedia
FDA
warnings
hepatitis C
AbbVie
Gilead Sciences
Harvoni
Viekira Pak
Flag link:
How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead
How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead
24/7 Wall St
FDA
Gilead Sciences
AbbVie
hepatitis C
warnings
Viekira Pak
Technivie
Flag link:
FDA issues warning on AbbVie hep C drugs and drugmaker's shares fall 10%
FDA issues warning on AbbVie hep C drugs and drugmaker's shares fall 10%
Fierce Pharma
FDA
hepatitis C
AbbVie
liver damage
Technivie
Viekira Pak
Flag link:
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Motley Fool
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
AbbVie
Viekira Pak
Achillion
Flag link:

Pages